Journal List > J Korean Ophthalmol Soc > v.59(1) > 1010914

TOOLS
Kang, Lee, and Lee: Optic Neuritis of Korean Adult
Original Article

Journal of the Korean Ophthalmological Society 2018; 59(1): 81-86.

Published online: 12 January 2018

DOI: https://doi.org/10.3341/jkos.2018.59.1.81

Optic Neuritis of Korean Adult

Tae-Seen Kang, MD, Woohyuk Lee, MD, Yeon-Hee Lee, MD, PhD

Department of Ophthalmology, Chungnam National University School of Medicine, Daejeon, Korea.

Address reprint requests to Yeon-Hee Lee, MD, PhD. Department of Ophthalmology, Chungnam National University Hospital, #282 Munhwa-ro, Jung-gu, Daejeon 35015, Korea. Tel: 82-42-280-8447, Fax: 82-42-255-3745, opticalyh@hanmail.net

Received 26 July 2017       Revised 10 October 2017       Accepted 15 December 2017

©2018 The Korean Ophthalmological Society

The Korean Ophthalmological Society

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

The aim of the study was to describe the clinical features and characteristics of optic neuritis patients compared with those of patients enrolled in the Optic Neuritis Treatment Trial (ONTT).

Methods

We retrospectively included consecutive patients diagnosed with optic neuritis between 2006 and 2015. The inclusion criteria were the same as those of the ONTT; an acute or subacute unilateral visual symptom ≤8 days in duration, a relative afferent pupillary defect, and a visual field defect in the affected eye.

Results

The 41 patients (14 females, 27 males) were of mean age 32.7 years. The incidence of papilledema was 58.5%, thus higher than that of ONTT patients (p = 0.004), and the incidence of ocular pain was 75.6%, lower than that of ONTT patients (p = 0.002). Six months after intravenous methylprednisolone therapy, 29 of 32 eyes (90.6%) recovered visual acuity of ≥1.0 or better, and only one eye exhibited poor visual acuity (≤0.5). Orbital magnetic resonance imaging (MRI) was performed on 34 patients, and most (91.2%) exhibited optic nerve enhancement. The three patients who did not exhibit enhancement reported no pain.

Conclusions

The clinical features of Korean optic neuritis patients differed from those of patients of the ONTT. Most patients exhibited optic nerve MRI enhancement associated with ocular pain. If enhancement of the optic nerve is lacking, diseases other than optic neuritis should be suspected because most optic nerves with neuritis exhibit enhancement on MRI.

Keywords: Optic neuritis, Optic Neuritis Treatment Trial (ONTT) study

Figures and Tables

Figure 1

Cumulative probability of patients with visual acuity of 20/20 in patients treated with intravenous high-dose methylprednisolone. Of our patients, 72% recovered to 20/20 or better at one month, 81% at two months, and 91% at six months.

jkos-59-81-g001
Table 1

Demographic and clinical characteristics of patients at the entry into study

jkos-59-81-i001

Values are presented as mean ± SD unless otherwise indicated.

ONTT = Optic Neuritis Treatment Trial; HFA = Humphrey field analyzer.

*Student t-test; †Chi-square test.

Table 2

Final visual acuity in the affected eyes in patients treated with intravenous high-dose methylprednisolone (p = 0.185*)

jkos-59-81-i002

ONTT = Optic Neuritis Treatment Trial.

*Fisher's exact test.

Table 3

Correlation between optic nerve enhancement on MRI and ocular pain (p = 0.009*)

jkos-59-81-i003

Values are presented as n (%) unless otherwise indicated.

MRI = magnetic resonance imaging.

*Fisher's exact test.

Notes

Conflicts of Interest The authors have no conflicts to disclose.

References

1. Hickman SJ, Miszkiel KA, Plant GT, Miller DH. The optic nerve sheath on MRI in acute optic neuritis. Neuroradiology. 2005; 47:51–55.
crossref
2. Hickman SJ, Dalton CM, Miller DH, Plant GT. Management of acute optic neuritis. Lancet. 2002; 360:1953–1962.
crossref
3. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008; 115:1079–1082.
4. Beck RW, Gal RL, Bhatti MT, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004; 137:77–83.
5. Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991; 109:1673–1678.
6. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992; 326:581–588.
7. Volpe NJ. The optic neuritis treatment trial: a definitive answer and profound impact with unexpected results. Arch Ophthalmol. 2008; 126:996–999.
8. Lee YJ, Kim MK, Hwang JM. Optic neuritis in Children. J Korean Ophthalmol Soc. 2002; 43:314–319.
9. Choi MY, Hwang JM. Clinical characteristics of optic neuritis associated with multiple sclerosis. J Korean Ophthalmol Soc. 2000; 41:1216–1223.
10. Ahn BC, Kim HS, Ahn HS. Clinical profile of the optic neuritis in Korea. J Korean Ophthalmol Soc. 1997; 38:1827–1833.
11. Cha DM, Kim SJ, Kim JH, et al. Clinical features and the effect of high-dose steroid therapy in Korean optic neuritis patients. J Korean Ophthalmol Soc. 2011; 52:1083–1088.
crossref
12. Kang HM, Kim HY. Clinical manifestations of idiopathic optic perineuritis in Korea. J Korean Ophthalmol Soc. 2012; 53:1016–1022.
crossref
13. Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol. 1993; 111:773–775.
14. Pau D, Al Zubidi N, Yalamanchili S, et al. Optic neuritis. Eye (Lond). 2011; 25:833–842.
crossref
15. Warren S, Warren KG. Prevalence of multiple sclerosis in Barrhead County, Alberta, Canada. Can J Neurol Sci. 1992; 19:72–75.
crossref
16. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001; 357:1576–1582.
crossref
17. Sandberg-Wollheim M, Bynke H, Cronqvist S, et al. A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol. 1990; 27:386–393.
crossref
18. Lim HC, Choi HY, Choi JH, Jung JH. Clinical manifestations and treatment of idiopathic optic perineuritis. J Korean Ophthalmol Soc. 2014; 55:891–897.
crossref
19. Lim SA, Goh KY, Tow S, et al. Optic neuritis in Singapore. Singapore Med J. 2008; 49:667–671.
20. Wakakura M, Minei-Higa R, Oono S, et al. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Jpn J Ophthalmol. 1999; 43:127–132.
crossref
21. Wang JC, Tow S, Aung T, et al. The presentation, aetiology, management and outcome of optic neuritis in an Asian population. Clin Exp Ophthalmol. 2001; 29:312–315.
crossref
22. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurology. 2003; 2:117–127.
crossref
23. Lin YC, Yen MY, Hsu WM, et al. Low conversion rate to multiple sclerosis in idiopathic optic neuritis patients in Taiwan. Jpn J Ophthalmol. 2006; 50:170–175.
crossref
24. Kim YM, Kim HY, Cho MJ, et al. Optic neuritis in Korean children: low risk of subsequent multiple sclerosis. Pediatr Neurol. 2015; 53:221–225.
crossref
25. Leibowitz U, Alter M, Halpern L. Clinical studies of multiple sclerosis in Israel. IV. Optic neuropathy and multiple sclerosis. Arch Neurol. 1966; 14:459–466.
TOOLS
Similar articles